{
    "paper_id": "72f778aaaef05178e9a5ad70714852d73a8c2e60",
    "metadata": {
        "title": "Les antir\u00e9troviraux ont-ils une place dans le traitement du syndrome respiratoire aigu s\u00e9v\u00e8re ?",
        "authors": [
            {
                "first": "Yazdan",
                "middle": [],
                "last": "Yazdanpanah",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Beno\u00eet",
                "middle": [],
                "last": "Gu\u00e9ry",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": ". Une r\u00e9surgence de l'\u00e9pid\u00e9mie de SRAS est possible.",
            "cite_spans": [],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Parmi les traitements antiviraux disponibles, la ribavirine a \u00e9t\u00e9 utilis\u00e9e chez les patients infect\u00e9s par le SRAS au d\u00e9but de l'\u00e9pid\u00e9mie. Le b\u00e9n\u00e9fice clinique de ce m\u00e9dicament n'a jamais \u00e9t\u00e9 montr\u00e9 [4, 5] . Les \u00e9tudes in vitro ont montr\u00e9 son inefficacit\u00e9 sur le SARS-CoV [6] . La ribavirine est associ\u00e9e \u00e0 une fr\u00e9quence \u00e9lev\u00e9e d'effets ind\u00e9sirables, parfois graves [7] . L'utilisation de la ribavirine n'est pas recommand\u00e9e. De nombreuses \u00e9quipes tentent d'identifier un traitement antiviral efficace. L'interf\u00e9ron et deux familles de traitements utilis\u00e9es chez les patients vivant avec le VIH: les inhibiteurs de prot\u00e9ases (IP) et les inhibiteurs d'entr\u00e9e, ont une activit\u00e9 potentielle [8] [9] [10] [11] [12] [13] [14] [15] .",
            "cite_spans": [
                {
                    "start": 198,
                    "end": 201,
                    "text": "[4,",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 202,
                    "end": 204,
                    "text": "5]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 271,
                    "end": 274,
                    "text": "[6]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 365,
                    "end": 368,
                    "text": "[7]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 687,
                    "end": 690,
                    "text": "[8]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 691,
                    "end": 694,
                    "text": "[9]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 695,
                    "end": 699,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 700,
                    "end": 704,
                    "text": "[11]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 705,
                    "end": 709,
                    "text": "[12]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 710,
                    "end": 714,
                    "text": "[13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 715,
                    "end": 719,
                    "text": "[14]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 720,
                    "end": 724,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "Quel traitement antiviral contre SARS-CoV?"
        },
        {
            "text": "L'inhibition d'une prot\u00e9ase ou d'une prot\u00e9ine de fusion est une approche g\u00e9n\u00e9rale en chimioth\u00e9rapie antivirale et n'est pas sp\u00e9cifique du VIH. Les mol\u00e9cules qui provoquent ces ph\u00e9nom\u00e8nes sont, en g\u00e9n\u00e9ral, tr\u00e8s sp\u00e9cifiques d'un virus ou d'une famille virale. Dans le traitement du SARS-CoV, l'\u00e9valuation de l'efficacit\u00e9 des anti-VIH, le virus pour lequel il existe le plus grand nombre de mol\u00e9cules, \u00e9tait essentiellement motiv\u00e9e par l'absence d'alternatives th\u00e9rapeutiques devant un virus \u00e9mergent, dans un contexte \u00e9pid\u00e9mique inqui\u00e9tant.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Place des inhibiteurs de prot\u00e9ases et des inhibiteurs de fusion dans le traitement du SARS-CoV"
        },
        {
            "text": "Le SARS-CoV contient une prot\u00e9ase virale (SARS-CL protease) qui intervient dans l'\u00e9tape d'assemblage des prot\u00e9ines virales [13] . Des travaux ont \u00e9t\u00e9 conduits pour rechercher une \u00e9ventuelle efficacit\u00e9 in vitro des IP commercialis\u00e9s, \u00e0 un stade pr\u00e9coce de d\u00e9veloppement, ou abandonn\u00e9s au cours de leur d\u00e9veloppement pour cause, notamment, d'effets secondaires. L'association lopinavir/ritonavir a \u00e9t\u00e9 la seule \u00e0 \u00eatre efficace in vitro [8, 10] . Des donn\u00e9es issues d'observations \u00e9pid\u00e9miologiques et cliniques allaient dans le sens de l'efficacit\u00e9 des multith\u00e9rapies antir\u00e9trovirales en g\u00e9n\u00e9ral et du lopinavir/ritonavir en particu-lier [10, 16, 17] . Une premi\u00e8re \u00e9tude a montr\u00e9 l'absence de contamination chez 19 patients s\u00e9ropositifs pour le VIH hospitalis\u00e9s au m\u00eame moment et au m\u00eame \u00e9tage d'un h\u00f4pital de Guangdong en Chine, qui accueillait des patients atteints de SRAS. Des contacts non prot\u00e9g\u00e9s avaient eu lieu entre les patients SRAS et les patients s\u00e9ropositifs pour le VIH [16, 17] . Parall\u00e8lement, 6 cas de SRAS ont \u00e9t\u00e9 observ\u00e9s chez les 28 personnels soignants ayant travaill\u00e9 au m\u00eame \u00e9tage (consid\u00e9r\u00e9s comme groupe t\u00e9moin). Compte tenu de ces observations, 2 hypoth\u00e8ses ont \u00e9t\u00e9 propos\u00e9es: l'interf\u00e9rence de l'infection par le VIH avec la r\u00e9plication du SARS-CoV pouvant emp\u00eacher le d\u00e9veloppement du SRAS, et/ou un \u00e9ventuel effet prophylactique des traitements antir\u00e9troviraux. Une autre \u00e9tude de Chu et al. a \u00e9valu\u00e9 l'efficacit\u00e9 clinique de lopinavir/ritonavir chez les patients infect\u00e9s par le SRAS [10] . Les auteurs ont observ\u00e9 un nombre significativement moins important de syndromes respiratoires aigus et de d\u00e9c\u00e8s (2,4 %) chez 41 patients atteints de SRAS recevant d\u00e8s l'admission un traitement par lopinavir/ritonavir (400/100 mg x 2/j) et ribavirine que dans une cohorte historique de 111 patients ayant re\u00e7u la ribavirine seule \u00e0 leur admission (28,8 %). Les \u00e9tudes in vitro plus r\u00e9centes n'ont pas confirm\u00e9 les donn\u00e9es des premi\u00e8res \u00e9tudes [9, 13] . La faible, voire l'absence d'efficacit\u00e9 in vitro de lopinavir/ritonavir, associ\u00e9e \u00e0 une CI50 d'environ 25 \u03bcm, a \u00e9t\u00e9 montr\u00e9e dans l'\u00e9tude men\u00e9e de Wu et al. [13] . Les autres IP et antir\u00e9troviraux commercialis\u00e9s n'ont jamais \u00e9t\u00e9 montr\u00e9s comme \u00e9tant efficaces in vitro [13] . Seul un IP en phase tr\u00e8s pr\u00e9coce de d\u00e9veloppement dans le VIH semble \u00eatre efficace et prometteur [13, 18] . L'\u00e9tude de Chen et al. rapportant l'absence de survenue des cas de SRAS chez 19 patients infect\u00e9s par le VIH ne peut pas conclure \u00e0 un effet prophylactique des traitements antir\u00e9troviraux car 8 des 19 patients de cette \u00e9tude ne recevaient pas de traitement antir\u00e9troviral [16, 17] . Parmi ceux qui recevaient un traitement antir\u00e9troviral, seuls deux recevaient un IP et il s'agissait de l'indinavir, qui n'a jamais montr\u00e9 d'efficacit\u00e9 in vitro. La survenue d'un plus grand nombre de cas de SRAS chez le personnel soignant par rapport aux patients s\u00e9ropositifs pour le VIH est difficilement interpr\u00e9table car le type de contact d'un soignant avec un patient ne peut \u00eatre compar\u00e9 aux contacts d'un patient avec un autre patient. Enfin, l'\u00e9tude de Chu et al. montrant l'efficacit\u00e9 clinique de lopinavir/ritonavir chez les patients infect\u00e9s par le SRAS \u00e9tait une comparaison historique [10] . La diff\u00e9rence constat\u00e9e entre les 2 groupes peut \u00eatre li\u00e9e \u00e0 une \u00e9volution dans le temps de la prise en charge des patients en g\u00e9n\u00e9ral et non au traitement par lopinavir/ritonavir. Compte tenu de l'absence de randomisation, la diff\u00e9rence de l'efficacit\u00e9 dans les deux groupes peut \u00eatre li\u00e9e \u00e0 des caract\u00e9ristiques diff\u00e9rentes des patients de ces deux groupes. D'autres \u00e9tudes fond\u00e9es sur des sch\u00e9mas d'\u00e9tudes plus robustes et un plus grand nombre de patients sont donc n\u00e9cessaires. Ces \u00e9tudes ne pouvaient bien s\u00fbr pas \u00eatre men\u00e9es au cours de la premi\u00e8re Mise au point infectiologie Les antir\u00e9troviraux ont-ils une place dans le traitement du syndrome respiratoire aigu s\u00e9v\u00e8re ? \u00e9pid\u00e9mie du SRAS, compte tenu de l'urgence dans laquelle se trouvaient les cliniciens, et de la m\u00e9connaissance de l'origine de l'\u00e9pid\u00e9mie au d\u00e9part.",
            "cite_spans": [
                {
                    "start": 123,
                    "end": 127,
                    "text": "[13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 434,
                    "end": 437,
                    "text": "[8,",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 438,
                    "end": 441,
                    "text": "10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 635,
                    "end": 639,
                    "text": "[10,",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 640,
                    "end": 643,
                    "text": "16,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 644,
                    "end": 647,
                    "text": "17]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 982,
                    "end": 986,
                    "text": "[16,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 987,
                    "end": 990,
                    "text": "17]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 1512,
                    "end": 1516,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 1962,
                    "end": 1965,
                    "text": "[9,",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1966,
                    "end": 1969,
                    "text": "13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 2128,
                    "end": 2132,
                    "text": "[13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 2239,
                    "end": 2243,
                    "text": "[13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 2343,
                    "end": 2347,
                    "text": "[13,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 2348,
                    "end": 2351,
                    "text": "18]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 2626,
                    "end": 2630,
                    "text": "[16,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 2631,
                    "end": 2634,
                    "text": "17]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 3236,
                    "end": 3240,
                    "text": "[10]",
                    "ref_id": "BIBREF10"
                }
            ],
            "ref_spans": [],
            "section": "Inhibiteurs de prot\u00e9ases"
        },
        {
            "text": "Le rationnel de l'utilisation des inhibiteurs d'entr\u00e9e dans le traitement du SARS-CoV, utilis\u00e9s plus tardivement que les IP et seulement in vitro, r\u00e9sulte de la d\u00e9couverte d'une similarit\u00e9 entre les s\u00e9quences des acides amin\u00e9s composant les domaines HR1 et HR2 de la gp 41 du VIH et la prot\u00e9ine de spicule de SARS-CoV [11] . La prot\u00e9ine de spicule de SARS-CoV est, comme la gp 41 dans le VIH, une glycoprot\u00e9ine de l'enveloppe virale qui permet la fusion de l'enveloppe du SARS-CoV et de la membrane cytoplasmique des cellules cibles. Comme dans le VIH, la prot\u00e9ine de spicule comporte deux domaines qui sont le HR1 et le HR2. Dans la pathologie VIH, la fusion du virus avec la membrane cytoplasmique des CD4 d\u00e9coule d'une interaction entre HR1 et HR2. Les inhibiteurs d'entr\u00e9e et notamment l'enfuviritide se fixent sur HR1 et emp\u00eachent la fixation du HR1 sur HR2 et sur la membrane de la cellule cible. Compte tenu de la similarit\u00e9 retrouv\u00e9e entre les s\u00e9quences des acides amin\u00e9s des domaines HR1 et HR2 de la gp 41 et de la prot\u00e9ine de spicule, la question soulev\u00e9e est la suivante : peut-on recourir aux inhibiteurs de fusion utilis\u00e9s dans le VIH ou comme dans le VIH synth\u00e9tiser des peptides correspondant aux s\u00e9quences des domaines HR1 et HR2 de la prot\u00e9ine de spicule et emp\u00eacher la fusion du SARS-CoV avec la membrane cytoplasmique des cellules cibles ? Les r\u00e9sultats pr\u00e9liminaires sont encourageants [11, [13] [14] [15] . Si aucune \u00e9tude n'a montr\u00e9 que l'enfuviritide pouvait \u00eatre efficace in vitro, un inhibiteur d'entr\u00e9e, en phase tr\u00e8s pr\u00e9coce de d\u00e9veloppement dans le VIH, semble \u00eatre prometteur [13, 19] . Des peptides correspondant aux s\u00e9quences des domaines HR1 et HR2 de la prot\u00e9ine de spicule ont \u00e9t\u00e9 synth\u00e9tis\u00e9s et semblent \u00eatre associ\u00e9s \u00e0 une efficacit\u00e9 antivirale [11, 14, 15] . Ces r\u00e9sultats sont tr\u00e8s en amont des phases cliniques et doivent \u00eatre confirm\u00e9 in vivo et dans les essais cliniques.",
            "cite_spans": [
                {
                    "start": 318,
                    "end": 322,
                    "text": "[11]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1407,
                    "end": 1411,
                    "text": "[11,",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1412,
                    "end": 1416,
                    "text": "[13]",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1417,
                    "end": 1421,
                    "text": "[14]",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1422,
                    "end": 1426,
                    "text": "[15]",
                    "ref_id": "BIBREF15"
                },
                {
                    "start": 1606,
                    "end": 1610,
                    "text": "[13,",
                    "ref_id": "BIBREF13"
                },
                {
                    "start": 1611,
                    "end": 1614,
                    "text": "19]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1782,
                    "end": 1786,
                    "text": "[11,",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1787,
                    "end": 1790,
                    "text": "14,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 1791,
                    "end": 1794,
                    "text": "15]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "Inhibiteurs d'entr\u00e9e"
        },
        {
            "text": "Au total, aucun des traitements commercialis\u00e9s dans la prise en charge des patients infect\u00e9s par le VIH ne semble efficace dans le traitement du SRAS. Les donn\u00e9es in vitro sont non concluantes et les donn\u00e9es cliniques fragiles. Des r\u00e9sultats pr\u00e9liminaires sur les IP et les inhibiteurs d'entr\u00e9e \u00e0 un stade pr\u00e9coce de d\u00e9veloppement ouvrent des perspectives int\u00e9ressantes. Les exp\u00e9riences acquises dans les domaines de recherche et d\u00e9veloppement pour le VIH ont certainement contribu\u00e9 aux avanc\u00e9es r\u00e9alis\u00e9es dans le d\u00e9veloppement des traitements antiviraux efficaces contre SARS-CoV. Si l'on assiste cette ann\u00e9e ou dans les ann\u00e9es \u00e0 venir \u00e0 une r\u00e9surgence du SARS, compte tenu des avanc\u00e9s r\u00e9alis\u00e9es dans cette p\u00e9riode post-\u00e9pid\u00e9mique, de multiples m\u00e9dicaments exp\u00e9rimentaux pourront \u00eatre test\u00e9s afin d'\u00e9valuer leur efficacit\u00e9 clinique.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Conclusion"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Conflits d'int\u00e9r\u00eat : aucun",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Identification of a novel coronavirus in patients with severe acute respiratory syndrome",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Drosten",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Gunther",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Preiser",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Van Der Werf",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "R"
                    ],
                    "last": "Brodt",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Becker",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "N Engl J Med",
            "volume": "348",
            "issn": "",
            "pages": "1967--76",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Probable cases of SARS by date of onset",
            "authors": [],
            "year": 2002,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF3": {
            "ref_id": "b3",
            "title": "Infectious diseases. Mounting lab accidents raise SARS fears",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Normile",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Science",
            "volume": "304",
            "issn": "",
            "pages": "659--61",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "Y"
                    ],
                    "last": "Hsu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "C"
                    ],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "A"
                    ],
                    "last": "Green",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Ang",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [
                        "I"
                    ],
                    "last": "Paton",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Emerg Infect Dis",
            "volume": "9",
            "issn": "",
            "pages": "713--720",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Booth",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Matukas",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Tomlinson",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "R"
                    ],
                    "last": "Rachlis",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "B"
                    ],
                    "last": "Rose",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "A"
                    ],
                    "last": "Dwosh",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "JAMA",
            "volume": "289",
            "issn": "",
            "pages": "2801--2810",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "SARS treatment: who will lead the way forward?",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Larkin",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Lancet Infect Dis",
            "volume": "3",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada",
            "authors": [
                {
                    "first": "S",
                    "middle": [
                        "R"
                    ],
                    "last": "Knowles",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [
                        "J"
                    ],
                    "last": "Phillips",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Dresser",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Matukas",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Clin Infect Dis",
            "volume": "37",
            "issn": "",
            "pages": "1139--1181",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study",
            "authors": [
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "T"
                    ],
                    "last": "Lai",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "E",
                    "middle": [],
                    "last": "Tsui",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Tam",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Hong Kong Med J",
            "volume": "9",
            "issn": "",
            "pages": "399--406",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Jiang",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "Y"
                    ],
                    "last": "Kao",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "T"
                    ],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "W"
                    ],
                    "last": "Fan",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "J Clin Virol",
            "volume": "31",
            "issn": "",
            "pages": "69--75",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Role of Lopinavir/Ritonavir in the treatment of SARS: initial virological and clinical findings",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "M"
                    ],
                    "last": "Chu",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [
                        "C"
                    ],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [
                        "F"
                    ],
                    "last": "Hung",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "H"
                    ],
                    "last": "Chan",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "S"
                    ],
                    "last": "Chan",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Thorax",
            "volume": "59",
            "issn": "",
            "pages": "252--258",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus : implications for virus fusogenic mechanism and identification of fusion inhibitors",
            "authors": [
                {
                    "first": "S",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Niu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "R"
                    ],
                    "last": "Escalante",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Lancet",
            "volume": "363",
            "issn": "",
            "pages": "938--985",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Loutfy",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [
                        "M"
                    ],
                    "last": "Blatt",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [
                        "A"
                    ],
                    "last": "Siminovitch",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Ward",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Wolff",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Lho",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "JAMA",
            "volume": "290",
            "issn": "",
            "pages": "3222--3230",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "Small molecules targeting severe acute respiratory syndrome human coronavirus",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "T"
                    ],
                    "last": "Jan",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [
                        "H"
                    ],
                    "last": "Ma",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "J"
                    ],
                    "last": "Kuo",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "F"
                    ],
                    "last": "Juan",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "S"
                    ],
                    "last": "Cheng",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Proc Natl Acad Sci USA",
            "volume": "101",
            "issn": "",
            "pages": "10012--10019",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein",
            "authors": [
                {
                    "first": "K",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Yi",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Qu",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Qing",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Biochem Biophys Res Commun",
            "volume": "319",
            "issn": "",
            "pages": "746--52",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "Following the rule : formation of the 6-helix bundle of the fusion core from severe acute respiratory syndrome coronavirus spike protein and identification of potent peptide inhibitors",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Xiao",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Yuan",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Biochem Biophys Res Commun",
            "volume": "319",
            "issn": "",
            "pages": "283--291",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Lack of severe acute respiratory syndrome in 19 AIDS patients hospitalized together",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "P"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "H"
                    ],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "P"
                    ],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Xiong",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [
                        "J"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "J Acquir Immune Defic Syndr",
            "volume": "34",
            "issn": "",
            "pages": "242--245",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome",
            "authors": [
                {
                    "first": "X",
                    "middle": [
                        "P"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                }
            ],
            "year": 2004,
            "venue": "Clin Infect Dis",
            "volume": "38",
            "issn": "",
            "pages": "1030--1032",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Brik",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Muldoon",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [
                        "C"
                    ],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Elder",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "S"
                    ],
                    "last": "Goodsell",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Olson",
                    "suffix": ""
                }
            ],
            "year": 2003,
            "venue": "Chembiochem",
            "volume": "4",
            "issn": "",
            "pages": "1246--1254",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Rapid diversity-oriented synthesis in microtiter plates for in situ screening: discovery of potent and selective alpha-fucosidase inhibitors",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "F"
                    ],
                    "last": "Chang",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Wong",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "Lin",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "TABREF0": {
            "text": "Yazdan Yazdanpanah, Service universitaire r\u00e9gional de maladies infectieuses et du voyageur, Centre hospitalier de Tourcoing, Facult\u00e9 de m\u00e9decine de Lille, 135 rue du Pr\u00e9sident Coty, 59 208 Tourcoing. Antiretroviral drugs in severe acute respiratory syndrome Inhibition of viral assembly (protease inhibitors) and of fusion of viral and target membranes (fusion inhibitors) are general approaches to antiviral treatment, not specific for HIV. Nonetheless, the agents that induce these phenomena are most often specific for a given virus or virus family. Drugs developed for HIV treatment were reevaluated for use against severe acute respiratory syndrome-coronavirus (SARS-CoV) during and after the epidemic in 2003, in view of the absence of any other available treatment. Of the protease and entry inhibitors approved for treating HIVinfected patients, none was effective against SARS-CoV, although in vitro activity against this virus was reported for the protease inhibitor lopinavir/ritonavir, in results that have not been confirmed in the most recent studies. The epidemiologic methods used to assess this drug's efficacy are not robust. Preliminary results for SARS treatment with protease and entry inhibitors, although at early stages of development, are promising. Yazdanpanah Y, Gu\u00e9ry B. Les antir\u00e9troviraux ont-ils une place dans le traitement du syndrome respiratoire aigu s\u00e9v\u00e8re ? Presse Med. 2006 ; 35 : 105-7.\u00a9 2006, Masson, Paris\u25a0 Points essentiels L'inhibition d'une prot\u00e9ase ou d'une prot\u00e9ine de fusion est une approche g\u00e9n\u00e9rale en chimioth\u00e9rapie antivirale et n'est pas sp\u00e9cifique du VIH. Les mol\u00e9cules qui provoquent ces ph\u00e9nom\u00e8nes sont, en g\u00e9n\u00e9ral, tr\u00e8s sp\u00e9cifiques d'un virus ou d'une famille virale. Dans le traitement du syndrome respiratoire aigu s\u00e9v\u00e8re (SRAS) li\u00e9s \u00e0 severe acute respiratory syndrome-Coronavirus (SARS-CoV), l'\u00e9valuation de l'efficacit\u00e9 des anti-VIH \u00e9tait essentiellement motiv\u00e9e par l'absence d'alternatives th\u00e9rapeutiques devant un virus \u00e9mergent, dans un contexte \u00e9pid\u00e9mique inqui\u00e9tant. Aucun des traitements commercialis\u00e9s dans la prise en charge des patients vivant avec le VIH ne semble efficace dans le traitement du du SARS-CoV. Les donn\u00e9es in vitro sont non concluantes et les donn\u00e9es cliniques fragiles. Des r\u00e9sultats pr\u00e9liminaires sur les inhibiteurs de prot\u00e9ase et les inhibiteurs d'entr\u00e9e \u00e0 un stade pr\u00e9coce de d\u00e9veloppement, tr\u00e8s en amont des phases cliniques, ouvrent des perspectives int\u00e9ressantes. premiers cas de syndrome respiratoire aigu s\u00e9v\u00e8re (SRAS) li\u00e9s \u00e0 severe acute respiratory syndrome-Coronavirus (SARS-CoV) sont apparus \u00e0 la mi-novembre 2002, en Chine [1]. La pand\u00e9mie du SRAS s'est ensuite r\u00e9pandue dans le monde, avec un total cumul\u00e9 de 8098 cas et 774 d\u00e9c\u00e8s notifi\u00e9s de la part des 28 pays affect\u00e9s, de novembre 2002 \u00e0 juillet 2003 [2]. Apr\u00e8s juillet 2003 et jusqu'en novembre 2005, seuls des cas isol\u00e9s et des cas group\u00e9s atteignant un faible nombre de personnes ont \u00e9t\u00e9 signal\u00e9s, toujours en Asie du Sud-Est, et le plus souvent li\u00e9s \u00e0 une exposition accidentelle lors d'une manipulation de laboratoire",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}